We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Needham & Company LLC from a “buy” ...

Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the ...

Biogen Idec Inc的股价已触及52周低点，交易价格为156.9美元，反映出这家生物技术公司正经历一段充满挑战的时期。过去一年，该公司股价下跌了31.68%，表明投资者存在重大担忧，市场压力较大。这一下滑发生在整个行业波动性较大的背景下，同时公司还面临着特定的障碍，包括竞争激烈的市场动态和产品管线的挫折。投资者正密切关注Biogen的战略举措，以重振增长并重获市场信心。 在其他近期新闻中 ...

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...

We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Investing.com - Needham downgraded Biogen Inc (NASDAQ: BIIB) on Monday, citing slower-than-expected growth for its ...